Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
284 8 |
Ultima descărcare din IBN: 2023-11-20 14:22 |
SM ISO690:2012 PELTEC, Angela, IVANOV, Victoria, MUNTEANU (IVANOV), Mihaela, PELTEC, Inesa, POPOVICI, Mihail. Monacolin K as a treatment of hyperlipidemia in patients with nonalcoholic fatty liver disease . In: Journal of Gastrointestinal and Liver Diseases, 2016, nr. S2(25), pp. 223-224. ISSN 1841-8724. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Journal of Gastrointestinal and Liver Diseases | ||||||
Numărul S2(25) / 2016 / ISSN 1841-8724 /ISSNe 1842-1121 | ||||||
|
||||||
Pag. 223-224 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background: Monacolin K is a fermented product of rice and red yeast (RYR) (Monascus purpureus). It is a potent inhibitor of HMG-CoA reductase – a substance that significantly reduces serum cholesterol levels, also known as lovastatin. Aim: To investigate the hypolipidemic effect of Monacolin K in patients with hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD). Methods: A total of 56 patients (mean age: 47.8 ± 1.8 years, 52 % males) who had a total cholesterol level of > 5.2 mmol/L and NAFLD were included in the study and allocated to receive Monacolin K 10 mg for 6 weeks. In all patients alcohol intake was reported to be less than 20 ml/day. We used ultrasound score as a criterion for NAFLD diagnosis. The 10-year risk of cardiovascular events was calculated according to the SCORE chart before and after treatment. As a primary outcome measure, we compared the before-after difference in lipid levels for patients included in the study. Results: Low density lipoprotein (LDL) cholesterol decreased from 4.19± 0.22 to 3.47± 0.14 mmol/L (-17.2%) (p<0.001), and total cholesterol from 6.46 ± 0.27 to 5.05± 0.16 mmol/L (-21.4%) (p<0.001). The lipid lowering effect resulted in a reduction of cardiovascular risk as measured with the SCORE chart, which changed from 3.85% to 2.5% . Conclusions: The RYR formulation under study was effective in lowering cholesterol and LDL cholesterol in patients with NAFDL. RYR therapy is an attractive alternative in patients with restrictions regarding pharmacological lipid lowering (high transaminase levels induced by NAFLD). |
||||||
|